1513 — Livzon Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Livzon Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	10,520	12,064	12,630	12,430	11,812
Cost of Revenue
Gross Profit	6,777	7,754	8,052	7,655	7,655
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	8,025	9,803	10,293	10,017	8,975
Operating Profit	2,496	2,261	2,337	2,413	2,837
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	2,489	2,246	2,331	2,383	2,806
Provision for Income Taxes
Net Income After Taxes	2,131	1,952	1,956	1,898	2,304
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,715	1,776	1,909	1,954	2,061
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,715	1,776	1,909	1,954	2,061
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.74	1.9	2.05	2.1	2.3
Dividends per Share